Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025
Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearn V. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR-/HER2– advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019 Oct;19(5):317-25. doi: 10.1016/j.clbc.2019.04.005
DiBenedetti DB, Soliman AM, Ervin C, Evans E, Coddington CC, Agarwal SK, Surrey ES, Taylor HS. Development of the Painful Periods Screening Tool for endometriosis. Postgrad Med. 2018 Nov;130(8):694-702. doi: 10.1080/00325481.2018.1526623
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Wollschlaeger BA, Ronquest NA, Montejano LB, Wilson TM, Nadipelli VR. Narcotic pain medication and other concomitant medication use before and after buprenorphine maintenance treatment initiation in patients with opioid dependence. Poster presented at the 2016 PAINWeek Conference; September 2016. Las Vegas, NV. [abstract] Postgrad Med. 2018 Aug; 128(Sup2):63-4. doi: 10.1080/00325481.2016.1224633
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Sheer R, Schwab P, Essex MN, Cappelleri J, Reiners A, Bobula J, Pasquale M. Acute pain management due to sprains, strains and contusions in the medicare population. Poster presented at the PAINWeek 2015; 2015. Las Vegas, NV. [abstract] Postgrad Med. 2015 Sep 4; 127(S1):S86. doi: https://doi.org/10.1080/00325481.2015.1086533
Digenio A, Karve S, Candrilli SD, Dalal M. Prandial insulin versus GLP-1 added to basal insulin: comparative effectiveness in the community practice setting. Postgrad Med. 2014 Oct;126(6):49-59.
Chopra I, Kamal KM, Candrilli SD, Kanyongo G. Association between obesity and therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Postgrad Med. 2014 Jan;126(1):66-77. doi: 10.3810/pgm.2014.01.2726.
Lanza LL, McQuay LJ, Rothman KJ, Bone HG, Kaunitz AM, Harel Z, Ataher Q, Ross D, Arena PL, Wolter KD. Comment on journal review of 'Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture'. J Fam Plann Reprod Health Care. 2013 Oct;39(4):306. doi: 10.1136/jfprhc-2013-100759
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.
Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med. 2011 May 1;123(3):122-32.
Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011 May 1;123(3):133-43.
Candrilli SD, Kuznik A, Mendys PM, Wilson DJ. Prevalence and coexistence of cardiovascular comorbidities among the US dyslipidemic population aged [greater than or equal to] 65 years by lipid-lowering medication use status. Postgrad Med. 2010 Sep 1;122(5):142-9.